Actinic Keratosis Global Market Report 2025

The actinic keratosis market size has grown steadily in recent years. It will grow from $7.95 billion in 2024 to $8.44 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to rising UV radiation exposure, an aging population, increasing awareness of skin cancer, a growing prevalence of actinic keratosis, expanding healthcare infrastructure, higher disposable incomes, supportive government initiatives, and a greater focus on preventive skincare.

The actinic keratosis market size is expected to see exponential growth in the next few years. It will grow to $10.58 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the emergence of innovative therapies, advancements in AI-powered diagnostic tools, increasing adoption of combination treatments, rising demand for non-invasive procedures, growing use of teledermatology, expanding application of photodynamic therapy, increased awareness of cosmetic outcomes, development of targeted biologic treatments, rising healthcare investment in emerging markets, and a growing focus on early detection and prevention. Major trends in the forecast period include AI-driven diagnostic tools, machine learning for lesion analysis, advanced photodynamic therapy systems, wearable UV monitoring devices, nanotechnology-based drug delivery, 3D imaging for personalized treatments, portable home-based phototherapy devices, biosensors for early detection, automated lesion classification software, and hydrogel-based therapeutic systems.

The growing number of severe sunburn cases is expected to drive the expansion of the actinic keratosis market in the future. Severe sunburns are intense skin burns resulting from excessive exposure to ultraviolet (UV) radiation, which leads to symptoms such as redness, pain, swelling, and occasionally blistering. These sunburns occur due to factors such as prolonged exposure to UV radiation, inadequate sun protection measures, increased outdoor activities during peak UV hours, and rising temperatures linked to climate change. UV radiation from sunburns damages the DNA in skin cells, causing mutations that disrupt normal cell function and contribute to the formation of precancerous lesions, particularly with repeated or extended sun exposure. For example, in May 2024, the UK-based charity Melanoma Focus reported 201 hospital admissions in 2022-23 due to sunburn, including 89 children and 25 infants under one year old. The charity also found that 66% of UK adults aged 16-65 recalled experiencing sunburn as children, with 65% reporting severe sunburn with blisters at least once, a figure that increased to 77% among those with light, pale, or white skin. As a result, the rising prevalence of severe sunburns is contributing to the growth of the actinic keratosis market.

Companies in the actinic keratosis market are focusing on the development of topical ointments that target and eliminate precancerous lesions more effectively, reduce recurrence rates, and improve patient adherence with shorter treatment periods and better safety profiles. These topical ointments are medicated creams or gels applied directly to affected skin areas, containing active ingredients such as tirbanibulin, which works by targeting abnormal keratinocytes to treat precancerous lesions. For instance, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) to extend the use of its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment is a microtubule inhibitor designed to prevent the proliferation of abnormal keratinocytes, effectively reducing the number and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, merged with Taro Pharmaceutical Industries Ltd. for $454 million. This merger aims to leverage Taro's expertise in dermatology and pediatrics, as well as its specialty and generic pharmaceuticals and over-the-counter products. Taro Pharmaceutical Industries Ltd, based in Israel, is focused on developing and manufacturing dermatology and topical treatment products, including those for actinic keratosis.

Major players in the actinic keratosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Amgen Inc., Bausch Health Companies Inc., Perrigo Company plc, Galderma SA, Incyte Corporation, Leo Pharma Inc., Almirall S.A., Athenex Inc., G&E Herbal Biotechnology Co. Ltd., Aclaris Therapeutics Inc., Biofrontera Inc., Hill Dermaceuticals Inc.

North America was the largest region in the actinic keratosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actinic keratosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the actinic keratosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Actinic keratosis (AK), also known as solar keratosis, is a common precancerous skin condition caused by prolonged exposure to ultraviolet (UV) radiation from the sun or artificial sources. It leads to rough, scaly, or crusty patches on sun-exposed areas of the skin, such as the face, scalp, hands, and arms. Actinic keratosis is considered an early stage of squamous cell carcinoma (SCC) and requires treatment to prevent progression. Regular skin checks and protection from sun exposure are important for managing and preventing the development of this condition.

The main types of treatment for actinic keratosis include topical treatments, surgical procedures, photodynamic therapy, and other options. Topical treatment typically involves applying creams or ointments directly to the affected skin areas. Distribution channels for these treatments include hospital pharmacies, drug stores, retail pharmacies, and online providers. End-users of these treatments include hospitals, dermatology clinics, spas and rejuvenation centers, home care settings, and others.

The actinic keratosis market research report is one of a series of new reports that provides actinic keratosis market statistics, including actinic keratosis industry global market size, regional shares, competitors with an actinic keratosis market share, detailed actinic keratosis market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis industry. This actinic keratosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actinic keratosis market consists of revenues earned by entities by providing services such as skin cancer screenings, cryotherapy, laser treatments, patient education programs and other medical procedures or products for prevention and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The actinic keratosis market also includes sales of cryosurgery devices, laser treatment systems, and sunscreen products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.